open access

Vol 10, Supp. C (2019)
Case report
Get Citation

Long-term response on brentuximab vedotin therapy in patients with Hodgkin lymphoma

Andrzej Pluta1, Justyna Gil, Jacek Krzanowski, Sławomir Radwański
DOI: 10.5603/Hem.2019.0020
Affiliations
  1. Oddział Hematologii Onkologicznej z Klinicznym Pododdziałem Przeszczepiania Szpiku, Szpital Specjalistyczny w Brzozowie, ul. ks. Bielawskiego, 36–200 Brzozów, Poland

open access

Vol 10, Supp. C (2019)
CASE REPORTS

Abstract

Progress in Hodgkin lymphoma (HL) treatment has been achieved due to introduction of new diagnostic methods, disease staging, and new therapy implementations. In spite of it, some patients are challenging in diagnostic and therapeutic process. The topic will provide a brief review of 2 young patients with HL who failed to achieve remission following few therapeutic treatment lines. Both of them response has been achieved when brentuximab vedotin was used. Many patients requires up to date new diagnostic methods implementation. Their interpretation is possible only in the context of clinical data.

Abstract

Progress in Hodgkin lymphoma (HL) treatment has been achieved due to introduction of new diagnostic methods, disease staging, and new therapy implementations. In spite of it, some patients are challenging in diagnostic and therapeutic process. The topic will provide a brief review of 2 young patients with HL who failed to achieve remission following few therapeutic treatment lines. Both of them response has been achieved when brentuximab vedotin was used. Many patients requires up to date new diagnostic methods implementation. Their interpretation is possible only in the context of clinical data.

Get Citation

Keywords

Hodgkin lymphoma (HL), brentuksymab vedotin (BV), autologous hematopoietic stem cell transplantation

About this article
Title

Long-term response on brentuximab vedotin therapy in patients with Hodgkin lymphoma

Journal

Hematology in Clinical Practice

Issue

Vol 10, Supp. C (2019)

Article type

Case report

Pages

17-20

Page views

388

Article views/downloads

127

DOI

10.5603/Hem.2019.0020

Keywords

Hodgkin lymphoma (HL)
brentuksymab vedotin (BV)
autologous hematopoietic stem cell transplantation

Authors

Andrzej Pluta
Justyna Gil
Jacek Krzanowski
Sławomir Radwański

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.